{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T07:26:57Z","timestamp":1790148417777,"version":"4.0.1"},"reference-count":59,"publisher":"BMJ","issue":"4","license":[{"start":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T00:00:00Z","timestamp":1777334400000},"content-version":"unspecified","delay-in-days":27,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100006108","name":"National Center for Advancing Translational Sciences","doi-asserted-by":"publisher","award":["K12TR004416"],"award-info":[{"award-number":["K12TR004416"]}],"id":[{"id":"10.13039\/100006108","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100015691","name":"Division of Microbiology and Infectious Diseases, National Institute of Allergy and Infectious Diseases","doi-asserted-by":"crossref","award":["R34AI148072"],"award-info":[{"award-number":["R34AI148072"]}],"id":[{"id":"10.13039\/100015691","id-type":"DOI","asserted-by":"crossref"}]},{"name":"U.S. National Institutes of Health: Division of Microbiology and Infectious Diseases, National Institute of Allergy and Infectious Diseases","award":["U01AI162457"],"award-info":[{"award-number":["U01AI162457"]}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2026,3,13]]},"published-print":{"date-parts":[[2026,4]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>\n                      Rates of sexually transmitted infections are on the rise globally, including those caused by\n                      <jats:italic>Neisseria gonorrhoeae<\/jats:italic>\n                      . Retrospective analyses across clinical settings around the world have indicated that rates of gonorrhoea declined following mass campaigns with vaccines made with outer membrane vesicles (OMV) from\n                      <jats:italic>N. meningitidis<\/jats:italic>\n                      serogroup B, a pathogen closely related to\n                      <jats:italic>N. gonorrhoeae<\/jats:italic>\n                      . The US Food and Drug Administration (FDA)-approved\n                      <jats:italic>N. meningitidis<\/jats:italic>\n                      serogroup B vaccine (4CMenB) contains\n                      <jats:italic>N. meningitidis<\/jats:italic>\n                      OMV and five recombinant protein components: factor H-binding protein (fHbp), Neisserial heparin-binding antigen (NHBA), Neisseria adhesin A (NadA) and the fusion partners genome-derived Neisseria antigen (GNA) 2091 and GNA1030 (used to stabilise fHbp and NHBA, respectively);\n                      <jats:italic>N. gonorrhoeae<\/jats:italic>\n                      encodes homologues of fHbp, NHBA, GNA2091 and GNA1030, but not NadA. Humans and mice immunised with 4CMenB have been shown to develop antibodies directed against\n                      <jats:italic>N. gonorrhoeae<\/jats:italic>\n                      antigens, and 4CMenB immunised mice exhibit enhanced\n                      <jats:italic>N. gonorrhoeae<\/jats:italic>\n                      clearance in a vaginal-infection model versus mock immunised mice. Collectively, these data led to the hypothesis that immunisation with 4CMenB may provide cross-protection against\n                      <jats:italic>N. gonorrhoeae<\/jats:italic>\n                      . There is a unique and time-sensitive opportunity to test the effectiveness of this vaccine in preventing\n                      <jats:italic>N. gonorrhoeae<\/jats:italic>\n                      using the human male urethral challenge model.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and analysis<\/jats:title>\n                    <jats:p>\n                      This is a double-blind randomised controlled trial testing the efficacy of the FDA-approved 4CMenB vaccine in preventing experimental\n                      <jats:italic>N. gonorrhoeae<\/jats:italic>\n                      infection. Our research team is currently the only in the world to use the established controlled human infection model to study\n                      <jats:italic>N. gonorrhoeae<\/jats:italic>\n                      in its natural human host. Males aged &gt;18\u2009years and &lt;36 years with no medical contraindication to 4CMenB administration, no contraindication to intraurethral challenge with\n                      <jats:italic>N. gonorrhoeae<\/jats:italic>\n                      and who are willing and able to consent and participate in the study will be enrolled in this study. Participants who complete both immunisation and\n                      <jats:italic>N. gonorrhoeae<\/jats:italic>\n                      challenge phases will be included in the primary endpoint analyses of\n                      <jats:italic>N. gonorrhoeae<\/jats:italic>\n                      infection in each study group to determine the efficacy of standard immunisation with 4CMenB in preventing experimental gonococcal infection. The secondary objective is to determine whether 4CMenB vaccinations change or delay the onset of urethritis symptoms.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Ethics and dissemination<\/jats:title>\n                    <jats:p>All participants enrolled in the study provided informed consent twice. This study has been reviewed and approved by the University of North Carolina at Chapel Hill Institutional Review Board (#21-0498). Data collection for this study is ongoing.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration number<\/jats:title>\n                    <jats:p>\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"clintrialgov\" specific-use=\"clinicaltrial \" xlink:href=\"NCT05294588\">NCT05294588<\/jats:ext-link>\n                      .\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjopen-2025-115296","type":"journal-article","created":{"date-parts":[[2026,5,3]],"date-time":"2026-05-03T10:18:16Z","timestamp":1777803496000},"page":"e115296","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":3,"title":["Efficacy of the serogroup B\n                    <i>Neisseria meningitidis<\/i>\n                    vaccine (4CMenB) in preventing experimental\n                    <i>Neisseria gonorrhoeae<\/i>\n                    urethral infection: a double-blind randomised controlled human challenge study protocol"],"prefix":"10.1136","volume":"16","clinical-trial-number":[{"clinical-trial-number":"nct05294588","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct05294588","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9219-6570","authenticated-orcid":false,"given":"Andreea","family":"Waltmann","sequence":"first","affiliation":[{"name":"Department of Medicine; Division of Infectious Diseases, The University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, North Carolina, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Kronk","sequence":"additional","affiliation":[{"name":"Department of Medicine; Division of Infectious Diseases, The University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, North Carolina, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dana","family":"Lapple","sequence":"additional","affiliation":[{"name":"Department of Medicine; Division of Infectious Diseases, The University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, North Carolina, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael P","family":"Motley","sequence":"additional","affiliation":[{"name":"Department of Medicine; Division of Infectious Diseases, The University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, North Carolina, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feng-Chang","family":"Lin","sequence":"additional","affiliation":[{"name":"Department of Biostatistics, Gillings School of Global Public Health, The University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arlene C","family":"Se\u00f1a","sequence":"additional","affiliation":[{"name":"Department of Medicine; Division of Infectious Diseases, The University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, North Carolina, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcia M","family":"Hobbs","sequence":"additional","affiliation":[{"name":"Department of Medicine; Division of Infectious Diseases, The University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, North Carolina, USA"},{"name":"Department of Microbiology and Immunology, The University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, North Carolina, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph A","family":"Duncan","sequence":"additional","affiliation":[{"name":"Department of Medicine; Division of Infectious Diseases, The University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, North Carolina, USA"},{"name":"Department of Pharmacology, School of Medicine, The University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA"},{"name":"Lineberger Comprehensive Cancer Center, The University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2026,4,28]]},"reference":[{"key":"2026042807301439000_16.4.e115296.1","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099"},{"key":"2026042807301439000_16.4.e115296.2","doi-asserted-by":"publisher","DOI":"10.2471\/BLT.18.228486"},{"key":"2026042807301439000_16.4.e115296.3","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.00010-14"},{"key":"2026042807301439000_16.4.e115296.4","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(24)00230-5"},{"key":"2026042807301439000_16.4.e115296.5","doi-asserted-by":"crossref","first-page":"S95","DOI":"10.1093\/cid\/ciac043","article-title":"Management of Neisseria gonorrhoeae in the United States: Summary of Evidence From the Development of the 2020 Gonorrhea Treatment Recommendations and the 2021 Centers for Disease Control and Prevention Sexually Transmitted Infection Treatment Guidelines","volume":"74","author":"Barbee","year":"2022","journal-title":"Clin Infect Dis"},{"key":"2026042807301439000_16.4.e115296.6","doi-asserted-by":"crossref","first-page":"e478","DOI":"10.1016\/S2666-5247(23)00370-1","article-title":"Antimicrobial-resistant Neisseria gonorrhoeae in Europe in 2020 compared with in 2013 and 2018: a retrospective genomic surveillance study","volume":"5","author":"Golparian","year":"2024","journal-title":"Lancet Microbe"},{"key":"2026042807301439000_16.4.e115296.7","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(24)00486-9"},{"key":"2026042807301439000_16.4.e115296.8","unstructured":"European Centre for Disease Prevention and Control . Extensively drug-resistant (XDR) Neisseria gonorrhoeae in the United Kingdom and Australia. Stockholm: ECDC, 2018."},{"key":"2026042807301439000_16.4.e115296.9","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMcp063561"},{"key":"2026042807301439000_16.4.e115296.10","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra0906357"},{"key":"2026042807301439000_16.4.e115296.11","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(02)08416-7"},{"key":"2026042807301439000_16.4.e115296.12","doi-asserted-by":"publisher","DOI":"10.1136\/adc.2006.111500"},{"key":"2026042807301439000_16.4.e115296.13","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(83)90340-9"},{"key":"2026042807301439000_16.4.e115296.14","doi-asserted-by":"publisher","DOI":"10.1128\/IAI.66.12.5939-5947.1998"},{"key":"2026042807301439000_16.4.e115296.15","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2009.04.071"},{"key":"2026042807301439000_16.4.e115296.16","doi-asserted-by":"publisher","DOI":"10.1016\/0264-410X(96)00001-1"},{"key":"2026042807301439000_16.4.e115296.17","doi-asserted-by":"publisher","DOI":"10.1016\/0140-6736(91)91961-S"},{"key":"2026042807301439000_16.4.e115296.18","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.4161\/hv.24129","article-title":"Vaccines against meningococcal serogroup B disease containing outer membrane vesicles (OMV): lessons from past programs and implications for the future","volume":"9","author":"Holst","year":"2013","journal-title":"Hum Vaccin Immunother"},{"key":"2026042807301439000_16.4.e115296.19","doi-asserted-by":"publisher","DOI":"10.1016\/0140-6736(92)93086-3"},{"key":"2026042807301439000_16.4.e115296.20","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2007.01.022"},{"key":"2026042807301439000_16.4.e115296.21","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)31449-6"},{"key":"2026042807301439000_16.4.e115296.22","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2018.1438028"},{"key":"2026042807301439000_16.4.e115296.23","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1097\/INF.0000000000003047","article-title":"VA-MENGOC-BC Vaccination Induces Serum and Mucosal Anti Neisseria gonorrhoeae Immune Responses and Reduces the Incidence of Gonorrhea","volume":"40","author":"Reyes D\u00edaz","year":"2021","journal-title":"Pediatr Infect Dis J"},{"key":"2026042807301439000_16.4.e115296.24","doi-asserted-by":"publisher","DOI":"10.1016\/s1473-3099(21)00754-4"},{"key":"2026042807301439000_16.4.e115296.25","doi-asserted-by":"publisher","DOI":"10.3201\/eid2206.151093"},{"key":"2026042807301439000_16.4.e115296.26","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(12)61961-8"},{"key":"2026042807301439000_16.4.e115296.27","doi-asserted-by":"publisher","DOI":"10.1016\/s1473-3099(21)00812-4"},{"key":"2026042807301439000_16.4.e115296.28","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciac436"},{"key":"2026042807301439000_16.4.e115296.29","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofx180.001"},{"key":"2026042807301439000_16.4.e115296.30","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1016\/S1473-3099(21)00744-1","article-title":"Public health impact and cost-effectiveness of gonorrhoea vaccination: an integrated transmission-dynamic health-economic modelling analysis","volume":"22","author":"Whittles","year":"2022","journal-title":"Lancet Infect Dis"},{"key":"2026042807301439000_16.4.e115296.31","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2018.03187","article-title":"Human Immune Responses and the Natural History of Neisseria gonorrhoeae Infection","volume":"9","author":"Lovett","year":"2018","journal-title":"Front Immunol"},{"key":"2026042807301439000_16.4.e115296.32","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1097\/OLQ.0000000000001973","article-title":"Estimates of the Lifetime Productivity Costs of Chlamydia, Gonorrhea, and Syphilis in the United States","volume":"51","author":"Chesson","year":"2024","journal-title":"Sex Transm Dis"},{"key":"2026042807301439000_16.4.e115296.33","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(24)00236-6"},{"key":"2026042807301439000_16.4.e115296.34","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciy1061"},{"key":"2026042807301439000_16.4.e115296.35","doi-asserted-by":"crossref","unstructured":"Marjuki H , Topaz N , Joseph SJ , et al . Genetic Similarity of Gonococcal Homologs to Meningococcal Outer Membrane Proteins of Serogroup B Vaccine. mBio 2019;10. doi:10.1128\/mBio.01668-19","DOI":"10.1128\/mBio.01668-19"},{"key":"2026042807301439000_16.4.e115296.36","doi-asserted-by":"crossref","DOI":"10.1128\/cmr.00094-23","article-title":"Neisseria gonorrhoeae vaccines: a contemporary overview","volume":"37","author":"Williams","year":"2024","journal-title":"Clin Microbiol Rev"},{"key":"2026042807301439000_16.4.e115296.37","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1008602","article-title":"The serogroup B meningococcal outer membrane vesicle-based vaccine 4CMenB induces cross-species protection against Neisseria gonorrhoeae","volume":"16","author":"Leduc","year":"2020","journal-title":"PLoS Pathog"},{"key":"2026042807301439000_16.4.e115296.38","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0603940103"},{"key":"2026042807301439000_16.4.e115296.39","doi-asserted-by":"publisher","DOI":"10.1126\/science.287.5459.1816"},{"key":"2026042807301439000_16.4.e115296.40","doi-asserted-by":"publisher","DOI":"10.1080\/14760584.2018.1547637"},{"key":"2026042807301439000_16.4.e115296.41","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2010.12.075"},{"key":"2026042807301439000_16.4.e115296.42","doi-asserted-by":"crossref","first-page":"4236","DOI":"10.1016\/j.vaccine.2017.06.020","article-title":"The role of anti-NHba antibody in bactericidal activity elicited by the meningococcal serogroup B vaccine, MenB-4C","volume":"35","author":"Partridge","year":"2017","journal-title":"Vaccine"},{"key":"2026042807301439000_16.4.e115296.43","doi-asserted-by":"crossref","DOI":"10.3390\/vaccines8020219","article-title":"The Neisseria gonorrhoeae Vaccine Candidate NHBA Elicits Antibodies That Are Bactericidal, Opsonophagocytic and That Reduce Gonococcal Adherence to Epithelial Cells","volume":"8","author":"Semchenko","year":"2020","journal-title":"Vaccines (Basel)"},{"key":"2026042807301439000_16.4.e115296.44","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1003528","article-title":"Distinct binding and immunogenic properties of the gonococcal homologue of meningococcal factor h binding protein","volume":"9","author":"Jongerius","year":"2013","journal-title":"PLoS Pathog"},{"key":"2026042807301439000_16.4.e115296.45","doi-asserted-by":"crossref","DOI":"10.1038\/s41541-024-01018-4","article-title":"NHBA antibodies elicited by 4CMenB vaccination are key for serum bactericidal activity against Neisseria gonorrhoeae","volume":"9","author":"Tzeng","year":"2024","journal-title":"NPJ Vaccines"},{"key":"2026042807301439000_16.4.e115296.46","doi-asserted-by":"crossref","first-page":"S152","DOI":"10.1093\/infdis\/jiab211","article-title":"Preclinical Testing of Vaccines and Therapeutics for Gonorrhea in Female Mouse Models of Lower and Upper Reproductive Tract Infection","volume":"224","author":"Connolly","year":"2021","journal-title":"J Infect Dis"},{"key":"2026042807301439000_16.4.e115296.47","doi-asserted-by":"crossref","DOI":"10.3389\/fmicb.2011.00123","article-title":"Experimental Gonococcal Infection in Male Volunteers: Cumulative Experience with Neisseria gonorrhoeae Strains FA1090 and MS11mkC","volume":"2","author":"Hobbs","year":"2011","journal-title":"Front Microbiol"},{"key":"2026042807301439000_16.4.e115296.48","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-4939-9496-0_25"},{"key":"2026042807301439000_16.4.e115296.49","doi-asserted-by":"crossref","unstructured":"Waltmann A , et al . Experimental Urethral Infection with Neisseria gonorrhoeae. Curr Top Microbiol Immunol 2022. doi:10.1007\/82_2021_250","DOI":"10.1007\/82_2021_250"},{"key":"2026042807301439000_16.4.e115296.50","doi-asserted-by":"crossref","DOI":"10.1128\/mBio.00892-13","article-title":"Lipid A\u2019s structure mediates Neisseria gonorrhoeae fitness during experimental infection of mice and men","volume":"4","author":"Hobbs","year":"2013","journal-title":"mBio"},{"key":"2026042807301439000_16.4.e115296.51","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2958.1998.00710.x"},{"key":"2026042807301439000_16.4.e115296.52","doi-asserted-by":"crossref","unstructured":"Waltmann A , Duncan JA , Pier GB , et al . Experimental urethral infection with neisseria gonorrhoeae (in press). In: Fabio Bagnoli GDG , Sanjay KP , Rino R , eds. Human challenge studies for vaccine development. Springer Nature, 2021.","DOI":"10.1007\/82_2021_250"},{"key":"2026042807301439000_16.4.e115296.53","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198506273122606"},{"key":"2026042807301439000_16.4.e115296.54","doi-asserted-by":"crossref","first-page":"S375","DOI":"10.1086\/513847","article-title":"Human experimentation with Neisseria gonorrhoeae: progress and goals","volume":"179 Suppl 2","author":"Cohen","year":"1999","journal-title":"J Infect Dis"},{"key":"2026042807301439000_16.4.e115296.55","doi-asserted-by":"publisher","DOI":"10.1172\/JCI117290"},{"key":"2026042807301439000_16.4.e115296.56","doi-asserted-by":"publisher","DOI":"10.1084\/jem.174.6.1601"},{"key":"2026042807301439000_16.4.e115296.57","first-page":"422","article-title":"Gonorrhoea in men: clinical and diagnostic aspects","volume":"72","author":"Sherrard","year":"1996","journal-title":"Genitourin Med"},{"key":"2026042807301439000_16.4.e115296.58","first-page":"184","article-title":"Some factors affecting the incubation period and duration of symptoms of urethritis in men","volume":"58","author":"Schofield","year":"1982","journal-title":"Br J Vener Dis"},{"key":"2026042807301439000_16.4.e115296.59","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmi.2017.02.020"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2025-115296","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,3]],"date-time":"2026-05-03T10:18:21Z","timestamp":1777803501000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2025-115296"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":59,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2026,4,28]]},"published-print":{"date-parts":[[2026,4]]}},"alternative-id":["10.1136\/bmjopen-2025-115296"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2025-115296","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"value":"2044-6055","type":"print"},{"value":"2044-6055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4]]}}}